Abstract 159P
Background
To overcome the common Temozolomide (TMZ) resistance in Glioblastoma (GBM), targeting certain receptors such as GPCRs can be of benefit as they are involved in cancer treatment response signalling pathways. One attractive target is KISS1R, activated by Kisspeptin. RNA-Seq of male GBM samples revealed elevated KISS1R expression and low KISS1 expression, suggesting GBM as a paracrine tumour. By re-modulating KISS1R using exogenous kisspeptin (KP-10), we aimed to positively influence the cytotoxic effect of TMZ and investigate the underlying mechanism(s) in KISS1R-expressing GBM cells.
Methods
KISS1R expression was confirmed using RT-PCR. KP-10/TMZ IC50 was determined using MTT cell viability assay and synergistic combinations were analysed using Isobologram analysis with non-constant ratio. Pathway prediction was done using KEGG, Wikipathways and STITCH. Flow cytometry and live-cell imaging identified molecular mechanisms while relevant markers were assessed via JESS simple Westren. LC-MS/MS was used to identify relevant DEPs with Kaplan-Meier survival analysis to identify clinical relevance.
Results
KISS1R expression was confirmed in A-172 (p53 wild-type) and LN-18 (p53 mutant). KP-10/TMZ treatment demonstrated high synergism in both cells. Pathway analysis of KP-10/TMZ predicted interaction at apoptosis, cytoprotective autophagy and DNA damage. This was further confirmed with elevated autophagy marker p62 in A-172, while increased expression of DNA damage and repair markers PARP and γH2AX in LN-18. The proteomic profiles showed DEPs related to RNA splicing, cytoplasmic translation and ER stress in A-172, while negative regulation of mRNA, glycolysis and MHC class 1 protein binding in LN-18. Ten common DEPs impacted GBM patients’ survival.
Conclusions
The response to KP-10/TMZ treatment varied based on the status of p53 of the GBM cell used and commonly impacted DEPs associated with the cytoplasmic translation of proteins and regulation of mRNA, more seen in LN-18 (p53 mutant). This underscores the significance of delving into the concept of dormant cells within a single tumour to correlate the results from the in-vitro GBM model to actual GBM patients.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JCSMHS, Monash University Seed Grand and Monash Merit scholarship and funding for doctoral research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract